



## Clinical trial results:

### Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer – Cachexia (NSCLC-C): A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients with NSCLC-C

#### Summary

EudraCT number	2010-023649-31
Trial protocol	HU GB PL
Global end of trial date	10 October 2014

#### Results information

Result version number	v1 (current)
This version publication date	28 October 2016
First version publication date	28 October 2016

#### Trial information

##### Trial identification

Sponsor protocol code	HT-ANAM-302
-----------------------	-------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01387282
WHO universal trial number (UTN)	-
Other trial identifiers	Other: ROMANA 2

Notes:

##### Sponsors

Sponsor organisation name	Helsinn Therapeutics (US), Inc.
Sponsor organisation address	170 Wood Avenue South, 5th Floor, Iselin, NJ, United States, 08830
Public contact	Richard K. Bourne, Ph.D., Helsinn Therapeutics (US), Inc., +1 732-603-2852, richard.bourne@helsinn.com
Scientific contact	Richard K. Bourne, Ph.D., Helsinn Therapeutics (US), Inc., +1 732-603-2852, richard.bourne@helsinn.com

Notes:

##### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	04 December 2014
Is this the analysis of the primary completion data?	Yes
Primary completion date	31 October 2013
Global end of trial reached?	Yes
Global end of trial date	10 October 2014
Was the trial ended prematurely?	No

Notes:

---

**General information about the trial**

---

Main objective of the trial:

1. To evaluate the effect of Anamorelin HCl on lean body mass (LBM) as measured by dual energy X-ray absorptiometry (DXA)
2. To evaluate the effect of Anamorelin HCl on muscle strength as measured by handgrip strength (HGS)

---

Protection of trial subjects:

The study was designed and monitored in accordance with Sponsor procedures, which comply with the ethical principles of Good Clinical Practice (GCP) as required by the major regulatory authorities, and in accordance with the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	14 July 2011
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	1 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	Poland: 203
Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	Hungary: 108
Country: Number of subjects enrolled	Australia: 22
Country: Number of subjects enrolled	Israel: 13
Country: Number of subjects enrolled	Russian Federation: 133
Country: Number of subjects enrolled	United States: 15
Worldwide total number of subjects	495
EEA total number of subjects	312

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	317
From 65 to 84 years	178
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Approximately 477 patients with advanced NSCLC-C (defined as unresectable Stage III and Stage IV and a weight loss of  $\geq 5\%$  body weight within 6 months prior to screening or a screening body mass index [BMI]  $< 20$  kg/m<sup>2</sup>) were to be randomized 2:1 to anamorelin HCl 100 mg or placebo.

### Pre-assignment

Screening details:

Central randomization stratified patients by geographic region, by chemotherapy and/or radiation therapy status and by weight loss over prior 6 months.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo

Arm description:

Placebo

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Matching placebo tablets.

<b>Arm title</b>	Anamorelin HCl
------------------	----------------

Arm description:

Active drug

Arm type	Experimental
Investigational medicinal product name	Anamorelin HCl
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Anamorelin HCl; 100 mg tablets; oral administration QD for 12 weeks, at least 1 hour before the first meal of the day.

<b>Number of subjects in period 1</b>	Placebo	Anamorelin HCl
Started	165	330
Completed	118	233
Not completed	47	97
Unrelated AE	4	6
Lost to follow-up	1	4
Death	16	47
Other	1	5
Study drug-related AE	2	2
Withdrawal by patient	23	33

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Placebo

Reporting group title	Anamorelin HCl
-----------------------	----------------

Reporting group description:

Active drug

Reporting group values	Placebo	Anamorelin HCl	Total
Number of subjects	165	330	495
Age categorical			
Units: Subjects			
≤ 65 years	108	209	317
> 65 years	57	121	178
Gender categorical			
Units: Subjects			
Female	43	90	133
Male	122	240	362
Race			
Units: Subjects			
White	162	326	488
Black or African American	1	2	3
Asian	1	0	1
Native Hawaiian or Other Pacific Islander	0	1	1
Other	1	1	2
Geographic region			
Units: Subjects			
North America	5	10	15
West Europe	75	142	217
East Europe + Russia	77	164	241
Australia	8	14	22

## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Placebo	
Reporting group title	Anamorelin HCl
Reporting group description:	
Active drug	
Subject analysis set title	ITT Population
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
The ITT Population included all randomized patients.	
Subject analysis set title	MITT Population
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
The MITT Population included all randomized patients who received any study drug and for whom at least 1 post-baseline co-primary efficacy variable (LBM or HGS) observation was obtained.	

### Primary: Change in Lean Body Mass

End point title	Change in Lean Body Mass
End point description:	
Change in Lean Body Mass (LBM) from baseline over 12 weeks for the ITT Population. Change from baseline over 12 weeks was defined as the average of the change from baseline at Week 6 and the change from baseline at Week 12.	
End point type	Primary
End point timeframe:	
Change in Lean Body Mass from Baseline Over 12 Weeks	

End point values	Placebo	Anamorelin HCl		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	157	321		
Units: kg				
median (confidence interval 95%)	-0.98 (-1.49 to -0.41)	0.65 (0.38 to 0.91)		

### Statistical analyses

Statistical analysis title	LBM statistical analysis
Comparison groups	Placebo v Anamorelin HCl

Number of subjects included in analysis	478
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Wilcoxon rank sum test

### Primary: Change in Handgrip Strength

End point title	Change in Handgrip Strength
End point description: Change in Handgrip Strength (HGS) of the non-dominant hand from baseline over 12 weeks for the ITT Population. Change from baseline over 12 weeks was defined as the average of the change from baseline at Week 6 and the change from baseline at Week 12.	
End point type	Primary
End point timeframe: Change in Handgrip Strength of the Non-Dominant Hand from Baseline Over 12 Weeks	

End point values	Placebo	Anamorelin HCl		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	157	321		
Units: kg				
median (confidence interval 95%)	-0.95 (-1.56 to 0.04)	-1.49 (-2.06 to -0.58)		

### Statistical analyses

Statistical analysis title	HGS statistical analysis
Comparison groups	Placebo v Anamorelin HCl
Number of subjects included in analysis	478
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.648
Method	Wilcoxon rank sum test

### Secondary: Change in A/CS Domain Score from Baseline

End point title	Change in A/CS Domain Score from Baseline
End point description: Change in the Functional Assessment of Anorexia/Cachexia Treatment (FAACT) 12-item Additional Concerns Subscale (A/CS) domain score from baseline overall (i.e., over 12 weeks) for the MITT Population.	
End point type	Secondary
End point timeframe: Change in FAACT A/CS Domain Score from Baseline Over 12 Weeks	



End point values	Placebo	Anamorelin HCl		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	136	268		
Units: score				
least squares mean (standard error)	1.34 ( $\pm$ 1.032)	3.48 ( $\pm$ 0.944)		

### Statistical analyses

Statistical analysis title	FAACT A/CS statistical analysis
Comparison groups	Placebo v Anamorelin HCl
Number of subjects included in analysis	404
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0016
Method	Mixed models analysis

### Secondary: Change in FACIT-F Fatigue Domain Score

End point title	Change in FACIT-F Fatigue Domain Score
End point description: Change in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) domain score from baseline overall (i.e., over 12 weeks) for the MITT Population.	
End point type	Secondary
End point timeframe: Change in FACIT-F Fatigue Domain Score from Baseline Over 12 Weeks	

End point values	Placebo	Anamorelin HCl		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	136	268		
Units: score				
least squares mean (standard error)	1.23 ( $\pm$ 1.293)	1.37 ( $\pm$ 1.169)		

### Statistical analyses

Statistical analysis title	FACIT-F statistical analysis
Comparison groups	Placebo v Anamorelin HCl

Number of subjects included in analysis	404
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8637
Method	Mixed models analysis

## Secondary: Change in Body Weight

End point title	Change in Body Weight
End point description:	Change in body weight (BW) from baseline overall (i.e., over 12 weeks) for the MITT Population.
End point type	Secondary
End point timeframe:	Change in Body Weight from Baseline Over 12 Weeks

End point values	Placebo	Anamorelin HCl		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	136	268		
Units: kg				
least squares mean (standard error)	-0.57 (± 0.438)	0.95 (± 0.386)		

## Statistical analyses

Statistical analysis title	BW statistical analysis
Comparison groups	Placebo v Anamorelin HCl
Number of subjects included in analysis	404
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Mixed models analysis

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse events that occurred during the clinical trial, commenced with the first dose of study drug through the 28 day post-treatment follow-up visit.

Adverse event reporting additional description:

Adverse events that occurred following the signature of the informed consent, but prior to the first dose of study drug were not reported as adverse events in this trial. The adverse event reporting period also ended if the patient began an alternative therapy within 28 days of the last administration of study drug.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	14
--------------------	----

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description: -

Reporting group title	Anamorelin HCl
-----------------------	----------------

Reporting group description: -

Reporting group title	Total: Placebo and Anamorelin HCl
-----------------------	-----------------------------------

Reporting group description:

TEAEs were defined as AEs with an onset date on or after the first dose date of the extension trial study drug and up to and including 7 days post-last dose date of the extension trial study drug.

Serious adverse events	Placebo	Anamorelin HCl	Total: Placebo and Anamorelin HCl
Total subjects affected by serious adverse events			
subjects affected / exposed	27 / 161 (16.77%)	73 / 330 (22.12%)	100 / 491 (20.37%)
number of deaths (all causes)	21	48	69
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm progression			
subjects affected / exposed	10 / 161 (6.21%)	25 / 330 (7.58%)	35 / 491 (7.13%)
occurrences causally related to treatment / all	0 / 10	0 / 25	0 / 35
deaths causally related to treatment / all	0 / 10	0 / 25	0 / 35
Gastric cancer			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epiglottic carcinoma			

subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Circulatory collapse			
subjects affected / exposed	1 / 161 (0.62%)	0 / 330 (0.00%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Hypotension			
subjects affected / exposed	1 / 161 (0.62%)	0 / 330 (0.00%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extremity necrosis			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 161 (0.00%)	3 / 330 (0.91%)	3 / 491 (0.61%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 3	0 / 3
Pyrexia			
subjects affected / exposed	0 / 161 (0.00%)	3 / 330 (0.91%)	3 / 491 (0.61%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1

Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	1 / 161 (0.62%)	1 / 330 (0.30%)	2 / 491 (0.41%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Pulmonary embolism			
subjects affected / exposed	0 / 161 (0.00%)	4 / 330 (1.21%)	4 / 491 (0.81%)
occurrences causally related to treatment / all	0 / 0	0 / 4	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary haemorrhage			
subjects affected / exposed	0 / 161 (0.00%)	5 / 330 (1.52%)	5 / 491 (1.02%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 5	0 / 5
Pneumothorax			
subjects affected / exposed	1 / 161 (0.62%)	0 / 330 (0.00%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemoptysis			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	0 / 161 (0.00%)	2 / 330 (0.61%)	2 / 491 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Completed suicide			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Confusional state			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Investigations			
Blood creatine increased			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood glucose increased			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Head injury			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	1 / 161 (0.62%)	1 / 330 (0.30%)	2 / 491 (0.41%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial tachycardia			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia paroxysmal			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cardiopulmonary failure			

subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Cardiac failure congestive			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Nervous system disorders			
Convulsion			
subjects affected / exposed	1 / 161 (0.62%)	1 / 330 (0.30%)	2 / 491 (0.41%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cerebrovascular insufficiency			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 161 (1.86%)	3 / 330 (0.91%)	6 / 491 (1.22%)
occurrences causally related to treatment / all	0 / 3	0 / 3	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	1 / 161 (0.62%)	2 / 330 (0.61%)	3 / 491 (0.61%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Febrile neutropenia			
subjects affected / exposed	2 / 161 (1.24%)	2 / 330 (0.61%)	4 / 491 (0.81%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Pancytopenia			

subjects affected / exposed	0 / 161 (0.00%)	2 / 330 (0.61%)	2 / 491 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Agranulocytosis			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 161 (0.00%)	2 / 330 (0.61%)	2 / 491 (0.41%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	1 / 161 (0.62%)	0 / 330 (0.00%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Haematuria			
subjects affected / exposed	1 / 161 (0.62%)	0 / 330 (0.00%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 161 (0.00%)	6 / 330 (1.82%)	6 / 491 (1.22%)
occurrences causally related to treatment / all	0 / 0	0 / 6	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 2	0 / 2



Sepsis			
subjects affected / exposed	1 / 161 (0.62%)	0 / 330 (0.00%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Tuberculosis			
subjects affected / exposed	1 / 161 (0.62%)	0 / 330 (0.00%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	1 / 161 (0.62%)	0 / 330 (0.00%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	1 / 161 (0.62%)	0 / 330 (0.00%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infective exacerbation of chronic obstructive airways disease			
subjects affected / exposed	1 / 161 (0.62%)	0 / 330 (0.00%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	1 / 161 (0.62%)	1 / 330 (0.30%)	2 / 491 (0.41%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Electrolyte imbalance			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus inadequate control			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 1
Hyperkalaemia			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	0 / 161 (0.00%)	1 / 330 (0.30%)	1 / 491 (0.20%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo	Anamorelin HCl	Total: Placebo and Anamorelin HCl
Total subjects affected by non-serious adverse events			
subjects affected / exposed	72 / 161 (44.72%)	156 / 330 (47.27%)	228 / 491 (46.44%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasm progression			
subjects affected / exposed	0 / 161 (0.00%)	2 / 330 (0.61%)	2 / 491 (0.41%)
occurrences (all)	0	2	2
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	21 / 161 (13.04%)	48 / 330 (14.55%)	69 / 491 (14.05%)
occurrences (all)	28	61	89
Leukopenia			
subjects affected / exposed	6 / 161 (3.73%)	25 / 330 (7.58%)	31 / 491 (6.31%)
occurrences (all)	7	29	36
Neutropenia			
subjects affected / exposed	10 / 161 (6.21%)	31 / 330 (9.39%)	41 / 491 (8.35%)
occurrences (all)	14	48	62
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	16 / 161 (9.94%)	29 / 330 (8.79%)	45 / 491 (9.16%)
occurrences (all)	19	30	49
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	13 / 161 (8.07%)	19 / 330 (5.76%)	32 / 491 (6.52%)
occurrences (all)	13	20	33
Vomiting			
subjects affected / exposed	9 / 161 (5.59%)	9 / 330 (2.73%)	18 / 491 (3.67%)
occurrences (all)	12	11	23
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	7 / 161 (4.35%)	13 / 330 (3.94%)	20 / 491 (4.07%)
occurrences (all)	8	15	23
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	14 / 161 (8.70%)	29 / 330 (8.79%)	43 / 491 (8.76%)
occurrences (all)	15	35	50

Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	3 / 161 (1.86%)	23 / 330 (6.97%)	26 / 491 (5.30%)
occurrences (all)	3	32	35

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 April 2012	Protocol amendment.

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported